tradingkey.logo

Qiagen NV

QGEN
查看詳細走勢圖
45.000USD
-0.220-0.49%
交易中 美東報價延遲15分鐘
9.76B總市值
24.10本益比TTM

Qiagen NV

45.000
-0.220-0.49%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.49%

5天

-4.28%

1月

+1.53%

6月

-4.48%

今年開始到現在

+1.07%

1年

-0.87%

查看詳細走勢圖

TradingKey Qiagen NV股票評分

單位: USD 更新時間: 2025-12-12

操作建議

Qiagen NV當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名29/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價50.65。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Qiagen NV評分

相關信息

行業排名
29 / 404
全市場排名
110 / 4592
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 18 分析師
買入
評級
50.653
目標均價
+10.45%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Qiagen NV亮點

亮點風險
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
估值低估
公司最新PE估值24.22,處於3年歷史低位
機構減倉
最新機構持股177.81M股,環比減少15.39%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉5.37K股

Qiagen NV新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Qiagen NV簡介

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
公司代碼QGEN
公司Qiagen NV
CEOBernard (Thierry)
網址https://www.qiagen.com/

常見問題

Qiagen NV(QGEN)的當前股價是多少?

Qiagen NV(QGEN)的當前股價是 45.000。

Qiagen NV 的股票代碼是什麼?

Qiagen NV的股票代碼是QGEN。

Qiagen NV股票的52週最高點是多少?

Qiagen NV股票的52週最高點是51.875。

Qiagen NV股票的52週最低點是多少?

Qiagen NV股票的52週最低點是37.630。

Qiagen NV的市值是多少?

Qiagen NV的市值是9.76B。

Qiagen NV的淨利潤是多少?

Qiagen NV的淨利潤為83.59M。

現在Qiagen NV(QGEN)的股票是買入、持有還是賣出?

根據分析師評級,Qiagen NV(QGEN)的總體評級為買入,目標價格為50.653。

Qiagen NV(QGEN)股票的每股收益(EPS TTM)是多少

Qiagen NV(QGEN)股票的每股收益(EPS TTM)是1.867。
KeyAI